Conference Proceedings

Optical Coherence Tomography in Patients With the Subretinal Implant Retina Implant Alpha IMS

Laura Kuehlewein, Veronique Kitiratschky, Mariya Gosheva, Thomas L Edwards, Robert E MacLaren, Markus Groppe, Akos Kusnyerik, Cristina Soare, Timothy L Jackson, Chen-Hsin Sun, Caroline Chee, Helmut Sachs, Krunoslav Stingl, Barbara Wilhelm, Florian Gekeler, Ulrich Bartz-Schmidt, Eberhart Zrenner, Katarina Stingl

OPHTHALMIC SURGERY LASERS & IMAGING RETINA | SLACK INC | Published : 2017

Abstract

BACKGROUND AND OBJECTIVE: The aim of this study was to assess changes in retinal structure and thickness after subretinal implantation of the Retina Implant Alpha IMS (Retina Implant AG, Reutlingen, Germany). PATIENTS AND METHODS: Spectral-domain optical coherence tomography (SD-OCT) imaging was performed to assess the structure and thickness of the retina anterior to the microphotodiode array preoperatively, within 6 weeks and 6 months ± 1 month after implantation. Thickness measurements were performed using the distance tool of the built-in software. Three thickness measurements were performed in each of the four quadrants of the retina on the microchip within 6 weeks and 6 months ± 1 mont..

View full abstract

Grants

Awarded by German Federal Ministry of Education and Research (BMBF)


Funding Acknowledgements

This manuscript presents data from a subanalysis of multicenter clinical trials (ClinicalTrials.gov NCT01024803 and NCT01497379) sponsored by Retina Implant AG. The clinical trial was also sponsored in part by the German Federal Ministry of Education and Research (BMBF; FKZ: 01GQ100L), by the Tistou and Charlotte Kerstan Foundation, and the Bernstein Center for Computational Neuroscience, Tuebingen. The sponsor(s) did not play a role in the design, collection, analysis and interpretation of data, or writing the manuscript of this subanalysis.Drs. Wilhelm and Kuehlewein received financial support from Retina Implant AG during the conduct of the study. Dr. Zrenner reports stock ownership in Retina Implant AG, and is a paid consultant, holder of patents as inventor/developer, and receives travel support from Retina Implant AG. Dr. Gekeler has stock ownership and is a paid consultant, holder of patents as inventor/developer, and receives travel support from Retina Implant AG. Dr. Sachs in on the advisory board for and receives travel compensation for lectures from Retina Implant AG outside the submitted work. Dr. Katarina Stingl is employed by Eberhard Karls University Tuebingen through funding provided by Retina Implant AG and has received travel cost reimbursement from the company, as well. Dr. Krunoslav Stingl is employed by Eberhard Karls University Tuebingen through funding provided by the Schumacher Foundation. Dr. Jackson has received grants from Retina Implant AG outside the submitted work and is the recipient of the Nuffield Medical Fellowship. The remaining authors report no relevant financial disclosures.